Novel quinazolinamide derivatives of the formula (I), in which R
1
-R
3
have the meanings indicated in Claim
1,
are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.
There is provided compounds of formula I,
wherein R
1
to R
7
have meanings given in the description, which are useful in the prophylaxis and in the treatment of arrhythmias, in particular atrial and ventricular arrhythmias.
The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
Compounds of the formula I Formula (I) wherein the substituents are as defined in claim 1, are useful as active ingredients, which have microbiocidal activity, in particular fungicidal activity.
DERIVATIVES OF AZASPIRANYL-ALKYLCARBAMATES OF 5-MEMBER HETEROCYCLIC COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
申请人:Abouabdellah Ahmed
公开号:US20110319381A1
公开(公告)日:2011-12-29
The invention relates to a compound of the general formula (I) in which R
2
is a hydrogen or fluorine atom or a hydroxyl, cyano, trifluoromethyl, C
1-6
-alkyl, C
1-6
-alkoxy, NR
8
R
9
group; m, n, o and p are independently an integer equal to 0, 1, 2 or 3; A is a covalent bond or a C
1-8
-alkylene group; R
1
is an optionally substituted aryl or heteroaryl group; R
3
is a hydrogen or fluorine atom or a C
1-6
-alkyl group or a trifluoromethyl group; R
4
is an optionally substituted 5-member heterocyclic compound; the compound being in the form of a base or acid addition salt. The invention also relates to the therapeutic use thereof.